scorecardresearch

Dr. Reddy’s Laboratories to commercialise novel molecule Tegoprazan in India

Meanwhile, HK inno.N Corporation will receive an upfront licensing fee. Additionally, it will also be eligible for potential regulatory milestone payments and royalties on net product sales.

Tegoprazan, dr reddy lab, gestrointestinal diseases, health news, pharma news,
HK inno.N Corporation’s Tegoprazan, a molecule containing novel potassium-competitive acid blockers (P-CABs), is an innovative potent, and highly selective inhibitor of gastric H+/K+-ATPase. (FE.com)

Dr. Reddy’s Laboratories Ltd. announced on Wednesday that it has entered into an exclusive partnership with South Korea-based HK inno.N Corporation, for the supply and commercialisation of HK inno.N Corporation’s patented novel molecule Tegoprazan for gastrointestinal diseases in India.

According to the company’s press statement, HK inno.N Corporation’s Tegoprazan, a molecule containing novel potassium-competitive acid blockers (P-CABs), is an innovative potent, and highly selective inhibitor of gastric H+/K+-ATPase.

Tegoprazan will provide a new option for the treatment of gastric acid-related and motility-impaired diseases such as Erosive/Non-erosive Gastroesophageal Reflux Disease (GERD / NERD), Gastric and Duodenal ulcers, Nonsteroidal anti-inflammatory drug-mediated ulcers, and Helicobacter pylori eradication,’ the company stated.

“Tegoprazan induces the fast onset of action and can control gastric pH for a prolonged period, potentially offering significant clinical benefit in acid-related disorders. Tegoprazan is already approved in South Korea and China and is under registration and clinical development in several countries globally, including the USA,” the company said in its press statement.

HK inno.N Corporation will be responsible for the manufacture and supply of Tegoprazan, while Dr. Reddy’s will be responsible for local clinical development, registration, marketing, and sales in the licensed territories as a condition of this partnership. Moreover, the agreement has also granted Dr. Reddy’s the exclusive rights to develop and commercialise Tegoprazan under its own trademark in these markets for 10 years from the first commercial launch.

Meanwhile, HK inno.N Corporation will receive an upfront licensing fee. Additionally, it will also be eligible for potential regulatory milestone payments and royalties on net product sales.

“Our partnership with HK inno.N Corporation brings their expertise in novel P-CABs together with our well-established commercial strengths and growth ambition in India and key emerging markets. Gastroenterology has been a key focus area for us. This collaboration is a multi-country deal for a novel molecule that addresses unmet needs in India and emerging markets as we continue our commitment to patients and our innovation agenda in keeping with our purpose of Good Health Can’t Wait,” M.V. Ramana, CEO – Branded Markets (India & Emerging Markets), Dr. Reddy’s, said in a statement.

“We are pleased to partner with Dr. Reddy’s for key Emerging Markets. The commercial strengths of Dr. Reddy’s makes it the ideal partner to commercialise our novel molecule Tegoprazan in these territories. With this collaboration, we look forward to further strengthening the value of our innovation in global markets,” Dal-Won Kwak, CEO, HK inno. N Corporation said in a statement.

Get live Share Market updates and latest India News and business news on Financial Express. Download Financial Express App for latest business news.

Most Read In India News